Y-Box binding protein 1 expression in breast cancer and its correlation with hormone receptors and other prognostic markers

• Published in: Journal of laboratory physicians 2018-10, Vol.10 (4), p.420-425
• Main Authors: Bansal, Taruna, Tanveer, Nadeem, Singh, Usha Rani, Sharma, Sonal, Kaur, Navneet
• Format: Article
• Language: English
• Subjects: Breast cancer; Care and treatment; Chromosomes; Drug resistance; Gene amplification; Gene expression; Hormones; Hybridization; Immunohistochemistry; Lymphatic system; manual tissue microarray; Medical prognosis; Original; Original Article; Patients; Prognosis; Protein binding; Protein expression; Proteins; Studies; triple-negative breast carcinoma; Tumors; y-box binding protein 1
• ISSN: 0974-2727; 0974-7826
• DOI: 10.4103/JLP.JLP_58_18

Abstract INTRODUCTION: The present histologic and immunohistochemical prognostic markers of breast carcinoma do not effectively identify the subset of patients with poor prognosis. Y-Box binding protein 1 (YB1) is a novel biomarker which may identify and aid in targeted personalized therapy for such patients. MATERIALS AND METHODS: The study was conducted on histopathology specimens of 74 patients of breast carcinoma who had undergone modified radical mastectomy. YB1 immunohistochemistry (IHC) was performed on manual tissue microarray blocks (each having 15 cores). The YB1 expression was quantified in terms of “immunoreactive score” which was correlated with clinical parameters, hormone receptor status, and Her2neu overexpression by IHC. The Her2neu status of the equivocal cases was further evaluated by fluorescent in situ hybridization (FISH). RESULTS: YB1 was positive in 36/74 (48.6%) cases. On IHC and analysis by FISH, 25/74 (34%) cases had Her2neu overexpression. Estrogen receptor (ER) and progesterone receptor (PR) positivity was found in 42% and 36.5% cases, respectively. YB1 immunopositivity was negatively correlated with ER and PR expression, but showed a significant positive correlation with Her2neu expression. No correlation was found with other clinical parameters, tumor stage, and grade, except lymph node involvement, which showed a positive association with YB1 expression. Triple-negative breast carcinoma constituted 25.6% of the total cases, out of which 73.6% were YB1 positive. CONCLUSION: This study found that YB1 has an association with Her2neu expression. It may in future provide a therapeutic target in Her2neu overexpressing tumors.